Feedback
Maternal T Cell Engraftment in SCID
2014699
Ordering Recommendation

Monitor engraftment of maternal T cells in patients with severe combined immunodeficiency (SCID) prior to allogenic stem cell transplantation.

Mnemonic
STR-SCID
Methodology
Polymerase Chain Reaction/Fragment Analysis
Performed
Sun-Sat
Reported
5-9 days
New York DOH Approval Status
Specimens from New York clients will be sent out to a New York DOH approved laboratory, if possible.
Submit With Order
ARUP Consult®
Disease Topics
Specimen Required
Patient Preparation
 
Collect
Lavender (EDTA), Pink (K2EDTA), Yellow (ACD Solution A), or buccal sample. 
Specimen Preparation
Transport 3 mL whole blood. (Min: 3 mL) Increase the amount of blood submitted for patients with low cell counts. 
Storage/Transport Temperature
Room temperature. Ship overnight. Specimens should be received within 24 hours of collection for optimal isolation of T cells. 
Unacceptable Conditions
Clotted or hemolyzed specimens. 
Remarks
Please provide the results and date of the patient's most recent WBC and differential counts. 
Stability
Ambient: 48 hours; Refrigerated: 48 hours; Frozen: Unacceptable 
Reference Interval
Type MaternalMaternal cells only.
Type PatientPatient cells only.
MixedPatient and Maternalt cells present.  Semi-quantitative results of percentage of patient and maternal cells will be reported.

Interpretive Data
Background Information for Maternal T Cell Engraftment in SCID:
Indication:
Severe combined immunodeficiency (SCID) patients lack T cells and cannot recognize and reject maternal T cells from maternal-fetal transfusion. Maternal T cell can proliferate in the absence of host T cells leading to difficulty in determining the host T cell numbers required for the diagnosis of SCID and/or can cause graft-versus-host (GVHD) like presentation.
Methodology:
PCR followed by capillary electrophoresis. Specimens are analyzed using 15 autosomal markers (D8S1179, D21S11, D7S820, CSF1PO, D3S1358, THO1, D13S317, D16S539, D2S1338, D19S433, vWa, TPOX, D18S51, D5S818, and FGA) and one gender marker (amelogenin).
Kit Used:
AmpFLSTR Identifiler® PCR Amplification Kit, Applied Biosystems.
Limit of Detection:
2 percent of minor cell population.

Compliance Statement B: For laboratory developed tests not using a RUO kit, and for FDA approved, cleared or 510(k) exempt assays with alterations. This test was developed and its performance characteristics determined by ARUP Laboratories. The U. S. Food and Drug Administration has not approved or cleared this test; however, FDA clearance or approval is not currently required for clinical use. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions.

Note
T cell genotypes will be compared to the patient's genotype obtained from a buccal sample and maternal genotypes. Therefore, patient peripheral blood and buccal sample and biological mother's specimens must be obtained and genotyped before the allogenic stem cell transplant event to treat SCID occurs. If T cell sorting is not completed before submission, BMT ISOL (2005498) will be added on to order.
Hotline History
View Hotline History
CPT Code(s)
81268; If cell sorting is performed, add 88184
Components
Component Test Code*Component Chart NameLOINC
2014700Specimen, Maternal Engraftment
2014701Mat Engraftment, Informative Loci
2014702Maternal Engraftment, Interpretation
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.
Aliases
  • Maternal engraftment
  • SCID engraftment